QGE031: Clinical Trials

10 trials of QGE031, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated, 1 withdrawn. 10 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Terminated 3, Withdrawn 1
Phase 11Completed 1

Follow QGE031: new trials by email Literature Review of QGE031 trials Research Report on QGE031

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Ligelizumab, Placebo - Chronic Spontaneous Urticaria
Phase 2CompletedNovartis Pharmaceuticals492018-08-012026-01-13
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Ligelizumab - Chronic Spontaneous Urticaria
Phase 2CompletedNovartis Pharmaceuticals2262016-05-242021-10-11
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
QGE031, Placebo - Asthma
Phase 2TerminatedNovartis Pharmaceuticals102015-09-012017-08-11
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
QGE031, Omalizumab, Placebo - Chronic Spontaneous Urticaria
Phase 2CompletedNovartis Pharmaceuticals3822015-07-152021-01-05
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
QGE031 - Asthma
Phase 2TerminatedNovartis Pharmaceuticals2702014-03-272017-08-11
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
QGE031, Placebo - Bullous Pemphigoid
Phase 2TerminatedNovartis Pharmaceuticals202013-01-012016-04-28
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
QGE031, Omalizumab, Placebo - Asthma
Phase 2CompletedNovartis Pharmaceuticals4712012-12-012017-08-11
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
QGE031, omalizumab, placebo - Allergic Asthma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals372012-11-012016-04-20
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
QGE031, Placebo, Cyclosporine A - Atopic Dermatitis
Phase 2CompletedNovartis Pharmaceuticals222012-01-052017-02-23
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
QGE031, Placebo - Peanut Allergy
Phase 2WithdrawnNovartis Pharmaceuticals2012-07-23

Conditions studied

Asthma (4)  ·  Chronic Urticaria (3)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  Hypersensitivity (2)  ·  Urticaria (2)  ·  Dermatitis, Atopic (1)  ·  Epilepsy, Idiopathic Generalized (1)  ·  Peanut Hypersensitivity (1)  ·  Pemphigoid, Bullous (1)  ·  Skin Diseases (1)

Sponsors

Novartis Pharmaceuticals (10)

Countries

Germany (8)  ·  Canada (7)  ·  United States (6)  ·  France (5)  ·  Russia (5)  ·  Hungary (4)  ·  Japan (4)  ·  Taiwan (4)  ·  United Kingdom (4)  ·  Argentina (3)  ·  Italy (3)  ·  Slovakia (3)  ·  Spain (3)  ·  Turkey (Türkiye) (3)  ·  Australia (2)

Results publications

PMID 34773261, PMID 36440464, PMID 31577874, PMID 37492920

NIH funding

2014 (2), 2015 (1), 2017 (1)